Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
05 mars 2021 17h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present in Upcoming Investor Conferences
19 févr. 2021 17h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares
10 févr. 2021 18h40 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
09 févr. 2021 23h58 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million
03 févr. 2021 23h35 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares
03 févr. 2021 17h51 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch
01 févr. 2021 07h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem
25 janv. 2021 07h00 HE
|
Iterum Therapeutics plc
-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 -- DUBLIN, Ireland and CHICAGO, Jan. 25, 2021 ...
Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference
06 janv. 2021 17h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors
23 déc. 2020 07h00 HE
|
Iterum Therapeutics plc
--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities-- DUBLIN, Ireland and...